Abiopharma

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan

Prelude Therapeutics Announces Strategic Business Update

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Veeva Basics Adopted by More Than 100 Emerging Biotechs to Simplify and Standardize Operations

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update